SAT0162 A POOLED ANALYSIS OF 1-YEAR CLINICAL OUTCOMES AMONG 6-MONTH RESPONDERS AND NON-RESPONDERS FROM THREE RANDOMISED CONTROLLED STUDIES OF TNF INHIBITOR BIOSIMILARS IN PATIENTS WITH RHEUMATOID ARTHRITIS
Published: Jun 1, 2019
Abstract
Background:
SB4, SB2, and SB5 are biosimilars of etanercept, infliximab, and adalimumab. Phase III randomised, double-blind studies were conducted to compare efficacy and safety between biosimilars and reference products.Objectives:
Assess and compare 1-year outcomes among 6-month responders and non-responders.Methods:
Patients who had 6-month data from each phase III study were pooled and categorised, based on their...Paper Details
Title
SAT0162 A POOLED ANALYSIS OF 1-YEAR CLINICAL OUTCOMES AMONG 6-MONTH RESPONDERS AND NON-RESPONDERS FROM THREE RANDOMISED CONTROLLED STUDIES OF TNF INHIBITOR BIOSIMILARS IN PATIENTS WITH RHEUMATOID ARTHRITIS
Published Date
Jun 1, 2019
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History